Al Mahtab Mamun, Rahim Md Abdur, Noor-E-Alam Sheikh Mohammad, Alam Mohammad Ashraful, Khondaker Faiz Ahmad, Moben Ahmed Lutful, Ghosh Jhumur, Khan Md Sakirul Islam
Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Department of Hepatology, Abdul Malek Ukil Medical College, Noakhali, Bangladesh.
Euroasian J Hepatogastroenterol. 2019 Jul-Dec;9(2):63-66. doi: 10.5005/jp-journals-10018-1300.
Although there are thousands of patients with hepatocellular carcinoma (HCC) in Bangladesh, almost there is no nationwide recommendations for therapeutic maneuver for HCC patients. As most of the HCC patients of Bangladesh are diagnosed late, patients with advanced HCC with large and multiple HCC nodules represent the usual presentation of HCC. The study is presented here to assess the effects of a combined therapy of transarterial chemoembolization (TACE) and sorafenib in advanced HCC patients.
A total of 77 patients with advanced HCC were enrolled in this study. All of them had advanced HCC with variable etiologies and clinical conditions. All patients were treated by TACE and also given systemic sorafenib at the same time. The patients were checked 1 and 3 months after therapy commencement.
Out of 77 patients, 18 patients died within 1 month and additional 15 patients died within 3 months after therapy commencement. Thus, there remains 44 surviving patients after 3 months. When different parameters of dead patients and survived patients were compared, no specific parameters dictated the factors about overall survival of more than 3 months.
This is the first approach to initiate an invasive and a systemic therapy for treatment of advanced HCC in Bangladesh. Further follow-up of patients and their long-term overall survival may cast some lights about the role of these therapies in Bangladeshi HCC patients.
Al Mahtab, M, Rahim MA, Noor-E-Alam SM, . Treatment by Transarterial Chemoembolization and Sorafenib for Hepatocellular Carcinoma vs Advanced Hepatocellular Carcinoma in Bangladesh: A Real-life Situation. Euroasian J Hepato-Gastroenterol 2019;9(2):63-66.
尽管孟加拉国有数千名肝细胞癌（HCC）患者，但几乎没有针对HCC患者治疗策略的全国性建议。由于孟加拉国的大多数HCC患者确诊较晚，晚期HCC伴大的和多发HCC结节的患者是HCC的常见表现形式。本文介绍该研究以评估经动脉化疗栓塞术（TACE）和索拉非尼联合治疗对晚期HCC患者的疗效。
本研究共纳入77例晚期HCC患者。他们均患有病因和临床状况各异的晚期HCC。所有患者均接受TACE治疗，同时给予索拉非尼全身治疗。在治疗开始后1个月和3个月对患者进行检查。
77例患者中，18例在治疗开始后1个月内死亡，另外15例在治疗开始后3个月内死亡。因此，3个月后有44例存活患者。比较死亡患者和存活患者的不同参数时，没有特定参数能决定超过3个月的总生存因素。
这是孟加拉国首次采用侵入性和全身治疗方法来治疗晚期HCC。对患者的进一步随访及其长期总生存情况可能会揭示这些治疗方法在孟加拉国HCC患者中的作用。
Al Mahtab, M, Rahim MA, Noor-E-Alam SM, 。经动脉化疗栓塞术和索拉非尼治疗孟加拉国肝细胞癌与晚期肝细胞癌：实际情况。《欧亚肝脏胃肠病学杂志》2019年；9(2):63 - 66。
